BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Healthtrust
Accenture
UBS
Argus Health
Chubb
Fuji
Julphar
Teva

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 207968

« Back to Dashboard

NDA 207968 describes JADENU SPRINKLE, which is a drug marketed by Novartis Pharms Corp and is included in one NDA. It is available from one supplier. There is one patent protecting this drug. Additional details are available on the JADENU SPRINKLE profile page.

The generic ingredient in JADENU SPRINKLE is deferasirox. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the deferasirox profile page.
Summary for 207968
Tradename:JADENU SPRINKLE
Applicant:Novartis Pharms Corp
Ingredient:deferasirox
Patents:1
Therapeutic Class:Antidotes, Deterrents, and Toxicologic Agents
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 207968
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
JADENU SPRINKLE deferasirox GRANULE;ORAL 207968 NDA Novartis Pharmaceuticals Corporation 0078-0713 0078-0713-15 30 PACKET in 1 CARTON (0078-0713-15) > 1 GRANULE in 1 PACKET (0078-0713-19)
JADENU SPRINKLE deferasirox GRANULE;ORAL 207968 NDA Novartis Pharmaceuticals Corporation 0078-0720 0078-0720-15 30 PACKET in 1 CARTON (0078-0720-15) > 1 GRANULE in 1 PACKET (0078-0720-19)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:GRANULE;ORALStrength90MG
Approval Date:May 18, 2017TE:RLD:Yes
Patent:➤ SubscribePatent Expiration:Apr 5, 2019Product Flag?YSubstance Flag?YDelist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:GRANULE;ORALStrength180MG
Approval Date:May 18, 2017TE:RLD:Yes
Patent:➤ SubscribePatent Expiration:Apr 5, 2019Product Flag?YSubstance Flag?YDelist Request?

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:GRANULE;ORALStrength360MG
Approval Date:May 18, 2017TE:RLD:Yes
Patent:➤ SubscribePatent Expiration:Apr 5, 2019Product Flag?YSubstance Flag?YDelist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Federal Trade Commission
Express Scripts
Chinese Patent Office
Mallinckrodt
US Army
McKesson
QuintilesIMS
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot